Case study: daratumumab in a relapsed patient
Overview of classical therapies for follicular lymphoma
Is venetoclax in combination with low-dose cytarabine a safe regimen for the treatment of AML?
Exciting advances in checkpint inhibitors CAR T-cells, and ALK inhibitors
Steven T. Rosen
The potential of biosimilar rituximab: reducing budgets and increasing access to treatment